A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

NCT05643742 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma
Non-Hodgkin Lymphoma
B-cell Malignancy
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Large B-cell Lymphoma

Interventions

BIOLOGICAL: CTX112

Sponsor

CRISPR Therapeutics AG